Skip to content
Precision for Medicine
ring-the-bel-3l pfm-homepage-mobile

Life-changing therapies
without a lifetime of
development

Precision for Medicine solves the most complex clinical development challenges to bring innovative therapies to patients. Contact Us

No one who is working to help patients in need should be subjected to unnecessary delays during clinical development and commercialization. Precision’s integrated capabilities, responsive operations and deep scientific expertise are helping life science innovators accelerate research and development while reducing cost and increasing the probability of approval.

Specialized capabilities for every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to increase speed to market. Precision brings a holistic view to your program's unique needs.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore
  • Discover Optimize early phase development
    Optimize early phase development

    Optimize early phase development

    How can you successfully navigate the complexities of early phase development? Integrated clinical and laboratory sciences capabilities are vital. Over 25 years of experience in early oncology development helps anticipate and mitigate a diverse set of risks, including complicated kitting and sample management.

    Discover
  • Discover Maximize late phase development
    Maximize late phase development

    Maximize late phase development

    Congratulations if you are entering late phase development. Now you’ll need a partner that can recruit patients most likely to respond to treatment, manage complex protocols, anticipate global regulatory requirements, enable manufacturing, support commercial viability and more. Let us drive your innovation to market and empower access for patients.

    Discover
human-

Trusted partner to leading innovators in oncology and rare disease

Clinical development is growing more complicated. Progress can hinge on the ability to navigate a shifting pathway to approval. Your path may be unique from those who have gone before, but our experience will help inform success. Precision is a leader in oncology and rare disease research. Our deep experience in complex indications accelerates the ability to reach key milestones, drive positive outcomes and most importantly, help patients get access to innovative treatments.

70 of clinical trials are in oncology
2500 clinical trial and lab projects
6 specialty labs in the US and Europe
30 in investments raised for biotech in the last 5 years
CRO Winner Badge@2x

Winner of the 2025 Fierce Biotech CRO Award for Innovative Solutions in Drug Development

Precision is dedicated to operational excellence and our collaborative approach to tackling complex challenges in oncology and rare disease research.

This recognition highlights our successful rescue of a high-risk hematology-oncology trial, where we conducted a full operational and data gap analysis, rebuilt sponsor alignment through proactive collaboration, implemented centralized patient-level data monitoring, and developed custom tracking systems to accelerate regulatory and startup activities.

We’re proud to help advance critical therapies and grateful to the sponsors, investigators, and teams who make this work possible.

Deep experience with debilitating disease and unique modalities

Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.

Insights for the greater good

We feel privileged to work in an industry that can change lives. When knowledge is shared, it is amplified. Expanding our collective intelligence can bring remedies to market faster. 

Read: Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy

Early Phase Research - Gene Therapies

Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1716454310949, hs_published_at=1753981935867, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins-White-150x150.jpeg',altText='Alexis-Hobbins-White-150x150',fileId=164710912635}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover
Read: Mining for Gold? Prospecting Biospecimen Collections to Power Precision Medicine Mining for Gold? Prospecting Biospecimen Collections to Power Precision Medicine

Translational Research - Biospecimens

Mining for Gold? Prospecting Biospecimen Collections to Power Precision Medicine

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=193399854592, hs_child_table_id=0, hs_updated_at=1753811966605, hs_published_at=1753981935867, description=George Rogers is a scientific storyteller with over two decades of experience translating complex biology into content that connects. At Precision for Medicine, he facilitates scientific content development, crafting articles, case studies and presentations that spotlight the company’s integrated support for sponsors, from biomarker discovery and translational science to clinical trial execution and regulatory guidance. George’s background in cell analysis and drug development informs his ability to turn complex science into clear, compelling narratives that support business development and drive engagement across the life sciences landscape., avatar=Image{width=800,height=798,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Geaorge%20W%20Rogers%2c%20PhD.jpg',altText='Geaorge W Rogers, PhD',fileId=193407923546}, lastname=Rogers, PhD, hs_initial_published_at=1753469768389, hs_created_by_user_id=26433386, hs_created_at=1753469702664, hs_is_edited=false, hs_deleted_at=0, name=George, job=Senior Manager, Scientific Content, slug=george-rogers-phd, hs_updated_by_user_id=51739740}, second={}, third={}})
  • George Rogers, PhD avatar

    George Rogers, PhD

Discover
Read: Case Study: Early Genotype Confirmation Rescued a Phase 1-2 SCID Trial Case Study: Early Genotype Confirmation Rescued a Phase 1-2 SCID Trial

Clinical Trials - Rare Diseases

Case Study: Early Genotype Confirmation Rescued a Phase 1-2 SCID Trial

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1716454310949, hs_published_at=1753981935867, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins-White-150x150.jpeg',altText='Alexis-Hobbins-White-150x150',fileId=164710912635}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover